Novel agent promising for the treatment of schizophrenia

Novel agent promising for the treatment of schizophrenia

(HealthDay)—For patients with an acute exacerbation of schizophrenia, SEP-363856, a non-D2-receptor-binding drug that has agonist activity at trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A receptors, reduces Positive and Negative Symptom Scale (PANSS) total score more than placebo, according to a study published in the April 16 issue of the New England Journal of Medicine.

Kenneth S. Koblan, Ph.D., from Sunovion Pharmaceuticals in Marlborough, Massachusetts, and colleagues conducted a randomized trial to assess the efficacy and safety of SEP-363856 in adults with an acute exacerbation of schizophrenia. Patients were randomly assigned to either once-daily SEP-363856 or placebo for four weeks (120 and 125 patients, respectively).

The researchers found that the mean change in the PANSS was −17.2 and −9.7 points, respectively, in the SEP-363856 and placebo groups (least-squares mean difference, −7.5 points). At week 4, the reductions in the Clinical Global Impressions Severity and Brief Negative Symptom Scale scores were generally in the same direction; the results were not adjusted for multiple comparisons. Somnolence and were included as adverse events with SEP-363856; there was one in the SEP-363856 group.

"The report by Koblan et al not only introduces a promising therapeutic compound but also provides additional evidence, on the basis of an agnostic drug-discovery process, that TAAR1 is a promising target," write the authors of an accompanying editorial.

The study was funded by Sunovion Pharmaceuticals, the developer of SEP-363856.


Explore further

Teprotumumab bests placebo for active thyroid eye disease

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: New England Journal of Medicine

Copyright © 2020 HealthDay. All rights reserved.

Citation: Novel agent promising for the treatment of schizophrenia (2020, April 16) retrieved 16 July 2020 from https://medicalxpress.com/news/2020-04-agent-treatment-schizophrenia.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
6 shares

Feedback to editors

User comments